Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
15.96% $6.32
America/New_York / 23 feb 2023 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 165.80 mill |
EPS: | 0.0600 |
P/E: | 105.33 |
Earnings Date: | May 04, 2023 |
SharesOutstanding: | 26.23 mill |
Avg Daily Volume: | 0.116 mill |
RATING 2023-02-27 |
---|
A+ |
Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Buy | |
DE: | Neutral | |
P/E: | Neutral | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 105.33 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
17.92x |
Company: PE 105.33 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 6.00 - 6.64 ( +/- 5.09%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-29 | Lyssikatos Joseph P | Sell | 12 000 | Stock Option (right to buy) |
2023-12-29 | Lyssikatos Joseph P | Buy | 12 000 | Common Stock |
2023-12-29 | Lyssikatos Joseph P | Sell | 9 151 | Common Stock |
2023-12-29 | Lyssikatos Joseph P | Sell | 2 849 | Common Stock |
2023-12-28 | Patel Anish | Sell | 2 520 | Common Stock |
INSIDER POWER |
---|
83.59 |
Last 97 transactions |
Buy: 15 631 291 | Sell: 878 871 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $6.32 (15.96% ) |
Volume | 0.272 mill |
Avg. Vol. | 0.116 mill |
% of Avg. Vol | 233.72 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.